The YRD motif is a major determinant of substrate and inhibitor specificity in T-cell protein-tyrosine phosphatase

被引:58
作者
Asante-Appiah, E
Ball, K
Bateman, K
Skorey, K
Friesen, R
Desponts, C
Payette, P
Bayly, C
Zamboni, R
Scapin, G
Ramachandran, C
Kennedy, BP
机构
[1] Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Pointe Claire, PQ H9R 4P8, Canada
[2] Merck Frosst Ctr Therapeut Res, Dept Med Chem, Pointe Claire, PQ H9R 4P8, Canada
[3] Merck Res Lab, Dept Endocrinol & Cell Biol, Rahway, NJ 07065 USA
关键词
D O I
10.1074/jbc.M011697200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We have studied T-cell protein-tyrosine phosphatase (TCPTP) as a model phosphatase in an attempt to unravel amino acid residues that may influence the design of specific inhibitors. Residues 48-50, termed the YRD motif, a region that is found in protein-tyrosine phosphatases, but absent in dual-specificity phosphatases was targeted. YRD derivatives of TCPTP were characterized by steady-state kinetics and by inhibition studies with BzN-EJJ-amide, a potent inhibitor of TCPTP, Substitution of Asp(50) to alanine or Arg(49) to lysine, methionine, or alanine significantly affected substrate hydrolysis and led to a substantial decrease in affinity for BzN-EJJ-amide, The influence of residue 49 on substrate/inhibitor selectivity was further investigated by comparing subsite amino acid preferences of TCPTP and its R49K derivative by affinity selection coupled with mass spectrometry, The greatest effect on selectivity was observed on the residue that precedes the phosphorylated tyrosine, Unlike wild-type TCPTP, the R49K derivative preferred tyrosine to aspartic or glutamic acid. BzN-EJJ-amide which retains the preferred specificity requirements of TCPTP and PTP1B was equipotent on both enzymes but greater than 30-fold selective over other phosphatases, These results suggest that Ar-49 and Asp(50) may be targeted for the design of potent and selective inhibitors of TCPTP and PTP1B.
引用
收藏
页码:26036 / 26043
页数:8
相关论文
共 31 条
[1]  
Ausubel F.M., 1992, SHORT PROTOCOLS MOL, V2nd
[2]   PROTEIN-TYROSINE PHOSPHATASES TAKE-OFF [J].
BARFORD, D ;
JIA, ZC ;
TONKS, NK .
NATURE STRUCTURAL BIOLOGY, 1995, 2 (12) :1043-1053
[3]   CD45-null transgenic mice reveal a positive regulatory role for CD45 in early thymocyte development, in the selection of CD4(+)CD8(+) thymocytes, and in B cell maturation [J].
Byth, KF ;
Conroy, LA ;
Howlett, S ;
Smith, AJH ;
May, J ;
Alexander, DR ;
Holmes, N .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (04) :1707-1718
[4]   [Difluro(phosphono)methyl]phenylalanine-containing peptide inhibitors of protein tyrosine phosphatases [J].
Desmarais, S ;
Friesen, RW ;
Zamboni, R ;
Ramachandran, C .
BIOCHEMICAL JOURNAL, 1999, 337 :219-223
[5]   THE DETERMINATION OF ENZYME INHIBITOR CONSTANTS [J].
DIXON, M .
BIOCHEMICAL JOURNAL, 1953, 55 (01) :170-171
[6]   Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene [J].
Elchebly, M ;
Payette, P ;
Michaliszyn, E ;
Cromlish, W ;
Collins, S ;
Loy, AL ;
Normandin, D ;
Cheng, A ;
Himms-Hagen, J ;
Chan, CC ;
Ramachandran, C ;
Gresser, MJ ;
Tremblay, ML ;
Kennedy, BP .
SCIENCE, 1999, 283 (5407) :1544-1548
[7]   Development of ''substrate-trapping'' mutants to identify physiological substrates of protein tyrosine phosphatases [J].
Flint, AJ ;
Tiganis, T ;
Barford, D ;
Tonks, NK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (05) :1680-1685
[8]  
Garton AJ, 1996, MOL CELL BIOL, V16, P6408
[9]  
GUAN KL, 1991, J BIOL CHEM, V266, P17026